Industry-Sponsored Research Week

Otsuka Pharma signs three-year partnership with Columbia U’s Mailman School of Public Health


By David Schwartz
Published: November 30th, 2020

Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) has inked an agreement with the Columbia University Irving Center Vagelos College of Physicians and Surgeons and Mailman School of Public Health to help support the epidemiological needs of Otsuka Global Pharmacovigilance (GPV). The three-year partnership will include product development and assessment, enhanced training, and employee education.

Faculty members from Columbia Mailman and the Columbia University Irving Medical Center’s Vagelos College of Physicians and Surgeons will work with Otsuka on activities such as post-marketing safety and effectiveness studies, the development of data registries, and investigations of rare exposures and outcomes. Columbia Mailman faculty will also provide executive education to Otsuka’s pharmacovigilance and clinical research and development employees, including conducting workshops in epidemiology and biostatistics, journal clubs, seminars, and formal courses.

“The expertise and scientific depth of the Columbia University Irving Medical Center faculty will help us enhance the epidemiological support for various Otsuka Global Pharmacovigilance regulatory reports and publications,” said Mirza I. Rahman, MD, MPH, Otsuka’s senior vice president and chief global pharmacovigilance officer, who is also a Columbia Mailman alumnus. “Patient safety is our highest priority, and the knowledge sharing, learning, and scientific exchange resulting from this initiative is consistent with Otsuka’s commitment to excellence in pharmacovigilance.”

OPDC is a subsidiary of Otsuka Pharmaceutical Co., Ltd., which focuses on unmet medical needs and nutraceutical products for the maintenance of everyday health. Its drug products address the challenging areas of mental, renal, and cardiovascular health, with additional research programs in oncology and on several under-addressed diseases including tuberculosis.

Leading Columbia Mailman School’s research team is Alfred I. Neugut, MD, PhD, MPH, professor of Epidemiology and Myron M. Studner, professor of cancer research in medicine at the Vagelos College of Physicians and Surgeons. “Our work with Otsuka is a unique and innovative approach to enhancing drug surveillance and safety efforts,” Neugut said.

Source: StreetInsider

Posted under: University-Industry Engagement Week

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment